UNSPSC 51321710: Atorvastatin magnesium

This classification denotes a hmg-coa reductase inhibitor 2C33H34FN2O5.Mg, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IVW98J023E, chemically known as magnesium, bis((.beta.r,.delta.r)-2-(4-fluorophenyl)-.beta.-(hydroxy-.kappa.o)-.delta.-hydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoato-.kappa.o1)-, (t-4)-, but more generally known as atorvastatin magnesium, which bears US NIH Compound Identifier 11651062.

UNSPSC 51321710 Atorvastatin magnesium is a Commodity code that covers pharmaceutical products, though recent state and local solicitations under this code address a broader scope of emergency medications and generic multi-source pharmaceuticals rather than atorvastatin specifically. State and local governments procure under this code through fire departments, emergency medical services, public health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The City of Tampa's Purchasing Department and Texas Health and Human Services Commission represent the issuing-body mix — municipal procurement offices and state health agencies — while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) signals the role of cooperative vehicles in aggregating demand across state and local members. Scope of work includes sealed-bid procurement of emergency life support medications with firm pricing, strict expiration-date warranties (typically nine months or more shelf life remaining at delivery), and rapid fulfillment (ten calendar days or less), as well as participation in statewide and multi-state pharmaceutical framework agreements that bundle generic drugs and over-the-counter products through authorized wholesaler channels and require compliance with cGMP, DSCSA, and FDA labeling standards.

Recent activity concentrates in Texas, Florida, and Minnesota. The City of Tampa issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem vials) with a response due April 8, 2026 and an estimated contract value of $40,000.00, including a 5 percent SLBE bid discount and one-year base term with two one-year renewal options. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to assess vendor capacity for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, reflecting emerging state interest in alternative pharmacy benefit procurement models. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be supplied through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness and awards effective July 1, 2026. These solicitations indicate steady demand for pharmaceutical supply contracts at municipal and state health levels, with growing emphasis on wholesale distribution networks and direct manufacturer engagement.